brazil regulatory approval

Sandoz confirms regulatory approval for new semaglutide treatment option in Brazil, paving way to expand patient access — Pho

Unlock Brazil's Semaglutide Approval in 30 Days

In 30 days, Sandoz’s semaglutide entered Brazil’s drug registry, instantly easing prescribing hurdles and opening the door for insurance coverage. The change reshapes how clinicians order, dispense, and get reimbursed for this GLP-1 therapy across public and private settings. Medical Disclaimer: This article is for informational purposes only